Competitive Technologies, Inc.

Competitive Technologies, Inc.

September 12, 2005 17:00 ET

Competitive Technologies Files Lawsuit against Carolina Liquid for Infringement

FAIRFIELD, Conn.--(CCNMatthews - Sep 12, 2005) -

Competitive Technologies, Inc. (AMEX: CTT) today announced that it had filed a complaint against Carolina Liquid Chemistries Corporation ("Carolina Liquid") of Brea, California, alleging patent infringement of CTT's U.S. Patent Number 4,940,658 covering homocysteine assays. The complaint was filed in the United States District Court for the District of Colorado. In the complaint, CTT seeks monetary damages, punitive damages, attorneys' fees, court costs and other remuneration at the option of the court. The homocysteine patent was derived from discoveries made by CTT's clients Drs. Robert Allen and Sally Stabler from the University of Colorado and the late Dr. John Lindenbaum from Columbia University.

"The filing of this complaint is part of our comprehensive and ongoing monitoring program to protect the patent rights of ourselves, our clients, and our current homocysteine licensees," said Aris D. Despo, CTT's Senior Vice President, Life Sciences. "While we believe that we already have licensed the majority of laboratories, distributors and other users of homocysteine assay tests in the Unites States, we continue our diligence in seeking those who use or sell tests without a license."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life and physical sciences, electronics, and nanotechnologies developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit our website at:

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on October 29, 2004, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:

Contact Information